Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock Options, Stock Purchase Plan and Warrants (Details Textual)

v2.4.0.6
Stock Options, Stock Purchase Plan and Warrants (Details Textual) (USD $)
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Stock option to purchase 1,298,000 519,000  
Deemed value per share $ 2.48    
Weighted average exercise price, granted $ 0.73 $ 0.51  
Stock compensation expense $ 575,000 $ 285,000  
Common stock, shares issued 45,280,280 43,416,200  
Shares were available for future option and stock awards under the Amended Plan 549,645    
Employee Stock Options, Stock Purchase Plan and Warrants (Textual) [Abstract]      
Common stock reserved and available for issuance under the Amended Plan 6,500,000    
Amended Plan expiration date Mar. 03, 2019    
Stock option Outstanding 5,777,214 4,779,170 5,470,044
Aggregate intrinsic value of all stock options outstanding and expected to vest 8,400,000    
Aggregate intrinsic value of currently exercisable stock options 6,900,000    
Total number of in the money options outstanding and exercisable 4,074,834    
Total intrinsic value of options exercised 264,000 126,000  
Total cash proceeds received from the exercise of stock options 201,000 367,000  
Total fair value of option shares vested 218,000 321,000  
Total fair value of options granted $ 943,000 $ 267,000  
Unrecognized stock-based compensation cost 615,000    
Unrecognized cost is expected to be recognized over a weighted-average period 1 year 7 months 6 days    
Supplemental options vested 200,000    
Purchase of shares under Warrant 450,000    
Value of warrant 0    
Albitar Warrant period 5 years    
Warrants Issued 348,417    
Exercise price 1.24    
Issuance of stock for stock options, shares 197,209 382,500  
Common stock, exercise price per share $ 1.02 $ 0.87 $ 0.87
Shares Issued under ESPP 56,805 122,401  
Minimum [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Options expiry period 5 years    
Stock option term 3 years    
Maximum [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Options expiry period 10 years    
Stock option term 4 years    
Plasma Prostate Cancer Test Licensed From Health Discovery Corp HDC [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Warrants Granted 80,000    
Colon Cancer Test Licensed From HDC [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Warrants Granted 40,000    
Pancreatic Cancer Test Licensed From HDC [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Warrants Granted 40,000    
Cytogenetics Automated Image Analysis Technology Licenses From HDC [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Warrants Granted 20,000    
Cytometry Automated Image Analysis Technology Licenses From HDC [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Warrants Granted 20,000    
Employee Stock Purchase Plan [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Limited payroll deductions a discount 5.00%    
Shares were available for future option and stock awards under the Amended Plan 0    
Warrant [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Stock option to purchase 200,000    
Deemed value per share $ 4.00    
Weighted average exercise price, granted $ 1.43    
Stock compensation expense 153,000 83,000  
Warrants Granted 200,000    
Common stock, shares issued 650,000    
Recorded stock based compensation expense 135,000    
Chief Medical Officer [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Stock option to purchase 250,000    
Stock option term 5 years    
Weighted average exercise price, granted $ 1.43    
Stock option vested 25.00%    
Stock option valued 310,000    
Stock compensation expense 151,000    
Chief Executive Officer [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Stock option to purchase 800,000    
Stock option term 5 years    
Deemed value per share $ 4.00    
Weighted average exercise price, granted $ 1.71    
Stock option valued 505,000    
Stock compensation expense $ 210,000    
Chief Scientific Officer [Member]
     
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]      
Options issued outside of the Amended Plan 350,000